ReviewInternational journal of molecular sciences2025
Pharmacological and Biological Efficacy of Chitosan-Based Materials.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Dual-functional Green Tea Polyphenol loaded Chitosan Nanoparticles for Eradication of Uropathogenic Biofilm and Induction of Apoptotic Pathways in Prostate Cancer Cells.Applied biochemistry and biotechnology · 2026Article
- Green Synthesis of Iron Oxide-Chitosan-Glutathione Nanosystem for Wound Healing Enhancement.Cell biochemistry and biophysics · 2026Article
- Review
- Advances in methotrexate nano-formulations to enhance therapeutic efficacy against drug-resistant breast cancer.Discover nano · 2026Review
- Research Progress on Self-Assembling Delivery Systems in Rheumatoid Arthritis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Chitosan (CS) is a biodegradable and biocompatible polysaccharide, obtained by the deacetylation of chitin. It has gained significant attention as a versatile material for biomedical applications due to its mucoadhesive properties, ease of chemical modification and intrinsic pharmacological activities. This review synthesizes two decades (2005-2025) of literature, focusing on chemical modifications of chitosan for pharmacological purposes and their therapeutic implications in non-communicable diseases (NCDs) and wound healing. Evidence highlights the roles of chitosan-based materials in anticancer, anti-inflammatory, antidiabetic, antihypertensive, and neuroprotective activities, alongside their integration in advanced wound healing strategies. Clinical trials have demonstrated the translational potential of chitosan-based materials. In general, chitosan-based materials exhibit promising dual functions as bioactive agents and drug carriers, necessitating additional investigation in clinical and regulatory frameworks to accelerate therapeutic adoption. In contrast to other studies, this study offers a mechanistic and integrative viewpoint that links chitosan's chemical modification techniques with their pharmacological effects and clinical translation potential, providing novel perspectives on structure-activity correlations and therapeutic design.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.